• Business Analysts

    BGSF (NYSE:BGSF) Might Be Having Difficulty Using Its Capital Effectively

    If you’re not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. If you see this, it typically means it’s a company with a great business model and plenty of profitable reinvestment opportunities. Although, when we looked at BGSF (NYSE:BGSF), it didn’t seem to tick all of these boxes. Understanding Return On Capital Employed (ROCE) If you haven’t worked with ROCE before, it  

    Comments Off on BGSF (NYSE:BGSF) Might Be Having Difficulty Using Its Capital Effectively
  • Business Analysts

    JPMorgan edges closer to leaving pandemic behind, its earnings show

    Oct 13 (Reuters) – JPMorgan Chase & Co (JPM.N) beat analysts’ profit estimates on Wednesday, thanks to record revenue in some investment banking businesses and a sunnier economic outlook that allowed the largest U.S. bank to release money it had set aside for potential loan losses during the coronavirus pandemic. JPMorgan’s third-quarter profit was 24% higher than the same period last year, and the bank’s average loans and deposits rose, as did credit-card spending, helping JPMorgan’s lending income rise 2.5% from the second quarter. On a call with analysts, executives were cautiously optimistic that the economy is finally on a  

    Comments Off on JPMorgan edges closer to leaving pandemic behind, its earnings show
  • Business Analysts

    Exploring the Career Opportunities for 2022

    A common factor between a data analyst and a business analyst is data science. Data science is already thriving in the emerging data-driven culture and has instigated companies to play with real-time data to drive revenue. Some organizations have started recruiting both data analysts and business analysts to gain a competitive edge in the market through customer satisfaction. A career as a data analyst and a career as a business analyst have shown huge potential and opportunities with lucrative salary packages. It may be a bit confusing to students who have just entered the domain of data science. Let’s explore  

    Comments Off on Exploring the Career Opportunities for 2022
  • Business Analysts

    Rising chip prices fuel Samsung’s best quarterly profit in 3 years

    Profit highest since 2018 but slightly below estimates Marketing costs may have offset foldable sales-analysts Falling memory chip prices to weigh on Q4-analysts SEOUL, Oct 8 (Reuters) – Samsung Electronics Co Ltd (005930.KS) on Friday flagged a 28% jump in its third-quarter operating profit to the highest in three years, driven by rising memory chip prices and display sales for new flagship smartphone launches. The preliminary result was up 26% from the second quarter, although just below forecasts, while the market reaction was further muted as analysts pencilled in a flat or slightly lower result this quarter on an expected  

    Comments Off on Rising chip prices fuel Samsung’s best quarterly profit in 3 years
  • Business Analysts

    Involvement Of Business Analysts In Software Development Life Cycle

    ABOUT SDLC   The significant interaction utilized by the software business for viable configuration, creation, and testing excellent software is known as Software Development Life Cycle.   Software Development Life Cycle is transcendently known for its acronym SDLC.   The point of utilizing SDLC by any association is to foster excellent software according to client needs. Different objectives of utilizing SDLC incorporate the finish of software in a decent time period and assessing costs precisely. The role of business analysts in SDLC makes the mentioned aspects more effective. You can begin your career as a business analyst by enrolling in a Business Analyst  

    Comments Off on Involvement Of Business Analysts In Software Development Life Cycle
  • Business Analysts

    A Skeptical Stock Analyst Wins Big by Seeking Out Frauds

    Last month, federal authorities charged the founder of the electric vehicle manufacturer Nikola, which had gone public in the summer of 2020, with defrauding investors. They were led there partly by the work of a little-known Wall Streeter named Nathan Anderson. A stock researcher and investor, Mr. Anderson and his upstart firm, Hindenburg Research, are having a moment. In early August, the Securities and Exchange Commission subpoenaed the sports betting firm DraftKings after Hindenburg said in a June report that it had potentially enabled black-market betting. And shares of Lordstown Motors have fallen nearly 70 percent since Hindenburg said in  

    Comments Off on A Skeptical Stock Analyst Wins Big by Seeking Out Frauds
  • Business Analysts

    Newsflash: Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Analysts Have Been Trimming Their Revenue Forecasts

    The analysts covering Eton Pharmaceuticals, Inc. (NASDAQ:ETON) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. After this downgrade, Eton Pharmaceuticals’ dual analysts are now forecasting revenues of US$24m in 2021. This would be a substantial 103% improvement in sales compared to the last 12 months. The losses are expected to disappear over the next year or so, with forecasts for a profit of US$0.02 per share  

    Comments Off on Newsflash: Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Analysts Have Been Trimming Their Revenue Forecasts
  • Business Analysts

    Q1 Earnings Weighed Down By U.S. Business, Analysts Cautious

    Most analysts downgraded or expect a limited upside for Lupin Ltd., citing uncertainties and contraction in the U.S. business. The drugmaker’s net profit rose 18% sequentially to Rs 542.5 crore in the quarter ended June, according to its exchange filing. That compares with the Rs 474.4-crore profit estimate of analysts tracked by Bloomberg. The bottom line of India’s sixth largest pharma company was aided by Rs 373.4 crore ($50 million) received from Boehringer Ingelheim towards successful achievement of key milestones for its clinical stage MEK inhibitor compound, the company said. Revenue rose 13% sequentially to Rs 4,237.4 crore. Analysts expected  

    Comments Off on Q1 Earnings Weighed Down By U.S. Business, Analysts Cautious